Phase III Study Comparing Perioperative FLOT Chemotherapy With or Without Intraoperative HIPEC in Patients with Resectable Diffuse or Mixed Type Gastric and Gastroesophageal Junction Type IIIII Adenocarcinoma
Led by Krankenhaus Nordwest · Updated on 2024-11-12
200
Participants Needed
15
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining perioperative FLOT chemotherapy with an intraoperative Hyperthermic IntraPEritoneal Chemoperfusion HIPEC procedure compared to FLOT chemotherapy alone in patients with resectable localized and locally advanced diffuse or mixed type adenocarcinoma of the stomach and Type IIIII gastroesophageal junction GEJ. This phase III, multicenter, randomized, open-label study focuses on patients who have received neoadjuvant FLOT therapy and do not have distant metastases, aiming to assess progression- and disease-free survival among other outcomes.
Participants receive 3 to 6 cycles of biweekly neoadjuvant FLOT chemotherapy before surgery. After tumor assessment, patients without disease progression are randomized to one of two groups Arm A continues with surgery followed by four cycles of postoperative FLOT chemotherapy, while Arm B undergoes surgery combined with intraoperative HIPEC using cisplatin at 426C for 90 minutes, followed by the same postoperative FLOT cycles. Surgery typically occurs 4 to 6 weeks after the last FLOT dose, and postoperative treatment begins within 6 to 12 weeks after surgery.
Throughout the study, tumor assessments using CT or MRI are performed before surgery and every three months afterward until progression, relapse, death, or study end. Clinical visits assess blood counts and toxicity before each treatment cycle. Safety monitoring includes tracking adverse and serious adverse events. Patient-reported quality of life and pain are measured regularly. The total follow-up extends up to five years to evaluate survival outcomes and relapse rates, with an initial safety phase after the first 20 patients receiving HIPEC.
CONDITIONS
Brief Title
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Research Team
T
Thorsten O Götze, MD
C
Claudia Pauligk, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed, resectable diffuse or mixed type adenocarcinoma of the gastroesophageal junction (AEG II-III) or stomach (uT3, uT4a, any N category, M0) or any T N+ M0 patient
Received 3 to 6 cycles of neoadjuvant FLOT chemotherapy (dose modifications allowed)
No prior cytotoxic or targeted therapy other than neoadjuvant FLOT
No previous partial or complete tumor resection
Male or female aged 18 to 75 years
Female patients with childbearing potential must have a negative pregnancy test within 7 days before study start
Agreement to use highly effective contraception during the study for patients of reproductive potential
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
No distant metastases confirmed by imaging and laparoscopic exclusion of peritoneal carcinomatosis
Adequate hematological, liver, and kidney function to allow surgery and HIPEC
Able and willing to provide written informed consent and comply with study procedures
You will not qualify if you...
No neoadjuvant therapy or neoadjuvant therapy other than FLOT
Known allergy or contraindication to 5-FU, leucovorin, oxaliplatin, or docetaxel
Significant active heart disease including cardiomyopathy, congestive heart failure (NYHA III-IV), or valvular defects
History of untreated or active other cancers within 3 years, except certain skin and cervical cancers
Tumors deemed primarily unresectable, including invasion of major blood vessels or adjacent organs (T4b) or distant lymph node metastases
Severe internal diseases or acute infections
Major surgery within 28 days before enrollment
Liver cirrhosis of Child-Pugh B or worse, or history of hepatic encephalopathy or ascites
Participation in another interventional clinical study within 30 days before and during this study
Pregnancy, breastfeeding, or planning pregnancy
Institutionalization by court or authority order
Concurrent antineoplastic treatments including radiation
Known intraabdominal adhesions or pre-existing peritoneal seeding
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Preoperative Chemotherapy
Duration - 6 to 12 weeks
Participants receive 3 to 6 cycles of biweekly FLOT chemotherapy prior to surgery.
3 to 6 visits (in-person) every 2 weeks
Preoperative Tumor Assessment
Duration - Within 2 weeks after preoperative chemotherapy
Tumor assessments including diagnostic laparoscopy are performed before surgery to confirm eligibility for randomization.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Surgery day plus hospital recovery
Participants undergo gastrectomy or transhiatal extended gastrectomy. In Arm B, surgery includes intraoperative HIPEC with heated cisplatin solution.
1 hospital stay for surgery
Postoperative Chemotherapy
Duration - 8 weeks (4 cycles)
Following surgery, participants receive four further 2-week cycles of FLOT chemotherapy starting 6 to 8 weeks after surgery, up to a maximum of 12 weeks.
4 visits (in-person) every 2 weeks
Radiological Tumor Assessments and Follow-up
Duration - Up to 5 years after randomization
Participants undergo CT or MRI tumor assessments every 3 months to monitor for progression, relapse, or survival status.
Quarterly visits every 3 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Safety and Effectiveness of Indocyanine Green Imaging in Advanced Gastric Cancer Surgery Using 3D and Ultra High Resolution Laparoscopy
Phase 12a Study of 64Cu-LNTH-1363S PETCT Imaging in Patients with Sarcoma or Gastrointestinal Tract Cancer
Evaluating Safety, Dosage, and Imaging Correlation with FAP Expression
Study of 18FFAPI PETCT and Laparoscopy to Improve Staging and Treatment Decisions in Advanced Gastric Cancer
Study of 18FFPyQCP PET Imaging for Fibroblast Activation Protein in Selected Cancers
Phase 2 Study of Systemic Chemotherapy, Immune Checkpoint Inhibitors, and HIPEC for Treating Gastric Cancer with Peritoneal Metastasis
Phase III Randomized Trial Comparing Albumin-bound Docetaxel and Taxotere for Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Mobile Capsule Gastroscopy to Detect Gastric Diseases in Elderly and High-Risk Adults
A Large Prospective Study in Community Health Centers
Phase 2 Study of SAR445877 as Monotherapy for Adults With Advanced Gastric or Gastroesophageal Junction Cancer in China
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
Thorsten O Götze, Pompiliu Piso, Sylvie Lorenzen...